New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
06:01 EDTCOVCovidien reports Q2 adjusted EPS 96c, consensus 95c
Reports Q2 revenue $2.60B, consensus $2.61B
News For COV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
13:31 EDTCOVCovidien announces mailing of definitive joint proxy statement, prospectus
Covidien (COV) announced, for purposes of the Irish Takeover Rules, that the definitive joint proxy statement of Covidien and Medtronic (MDT), which also serves as a prospectus of Medtronic Holdings Limited and comprises Covidienís scheme circular required under Irish law is being sent today to Covidien and Medtronic shareholders. As previously announced, on June 15, Covidien and Medtronic entered into a definitive agreement pursuant to which Medtronic Holdings Limited, a new holding company incorporated in Ireland that will be renamed Medtronic plc, will acquire Covidien and Medtronic. The joint proxy statement/prospectus will contain important information about the transaction for shareholders of both companies, as well as notices of the shareholder meetings and instructions on voting online, by mail, by telephone or in person.
November 20, 2014
05:14 EDTCOVCovidien achieves CE Mark for Nellcor Bedside SpO2 Patient Monitoring System
Subscribe for More Information
November 19, 2014
08:15 EDTCOVMedtronic reported solid Q2 results, says Bernstein
Bernstein notes that Medtronic's (MDT) sales growth accelerated to 5%, and the firm thinks the company's market share of the ICD market is poised to increase next quarter. Bernstein views Medtronic as "a strong buy" into the close of its acquisition of Covidien (COV). The firm reiterates an Outperform rating on Medtronic.
06:54 EDTCOVMedtronic reiterated as a top pick at JPMorgan
Subscribe for More Information
November 18, 2014
12:08 EDTCOVOn The Fly: Midday Wrap
Subscribe for More Information
09:08 EDTCOVMedtronic says regulatory processes for Covidien deal 'all on track'
Subscribe for More Information
07:20 EDTCOVMedtronic confirms commitment to Covidien transaction
Subscribe for More Information
November 14, 2014
17:27 EDTCOVPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
12:43 EDTCOVMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTCOVMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information
November 13, 2014
18:07 EDTCOVCovidien' VenaSeal closure system shows positive results
Covidien announced the six-month results of the VeClose pivotal study of the safety and effectiveness of the VenaSeal closure system in patients with chronic venous insufficiency having symptomatic reflux in the great saphenous vein. The VeClose randomized controlled non-inferiority study compared the safety and effectiveness of the VenaSeal system to that of the ClosureFast endovenous radiofrequency ablation catheter. Covidien's ClosureFast catheter is an endovenous radiofrequency ablation catheter designed to collapse and close enlarged leg veins. The VenaSeal system is not approved and currently limited to investigational use in the U.S. At three months, the complete closure of the great saphenous veins achieved in more than 98.9% of patients treated with the VenaSeal system compared to 95.6% of patients treated with the ClosureFast catheter. The closure rate at six months was 98.9% and 94.3%.
13:27 EDTCOVMedtronic likely to continue to make new highs, Barron's says
Subscribe for More Information
November 11, 2014
07:24 EDTCOVMedtronic submits commitments to EU related to Covidien merger
Subscribe for More Information
November 10, 2014
15:54 EDTCOVAmerican Society of Nephrology to hold a conference
Subscribe for More Information
08:36 EDTCOVBSD Medical names Clint Carnell as president and CEO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use